Your browser doesn't support javascript.
loading
The Systemic Immune Markers at Diagnosis Can Predict the Survival Benefit in Advanced Breast Cancer.
Nakamoto, Shogo; Ikeda, Masahiko; Kubo, Shinichiro; Yamamoto, Mari; Yamashita, Tetsumasa; Kuwahara, Chihiro.
Affiliation
  • Nakamoto S; Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
  • Ikeda M; Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
  • Kubo S; Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
  • Yamamoto M; Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
  • Yamashita T; Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
  • Kuwahara C; Division of Breast and Thyroid Gland Surgery, Fukuyama City Hospital, Hiroshima, Japan.
Cancer Diagn Progn ; 1(5): 471-478, 2021.
Article in En | MEDLINE | ID: mdl-35403159
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Cancer Diagn Progn Year: 2021 Document type: Article Affiliation country: Japan
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Language: En Journal: Cancer Diagn Progn Year: 2021 Document type: Article Affiliation country: Japan